Applied and environmental microbiology

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Viruses

molecular and cellular probes

Antiviral research

iranian journal of allergy, asthma, and immunology

journal of the pediatric infectious diseases society

[1] Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.

[2] In silico structure-based design and synthesis of novel anti-RSV compounds.

[3] Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort.

[4] Multiple Respiratory Syncytial Virus Introductions Into a Neonatal Intensive Care Unit.

[5] Whole genome comparisons of isolates from cattle and chickens.

[6] modified vaccinia virus ankara (mva) as production platform for vaccines against influenza and other viral respiratory diseases

[7] time series analysis of rsv and bronchiolitis seasonality in temperate and tropical western australia

[8] two cases of pneumatoceles in mechanically ventilated infants

[9] transient depletion of cd169+ cells contributes to impaired early protection and effector cd8+ t cell recruitment against mucosal respiratory syncytial virus infection

[10] rs virus diagnosis: comparison of isolation, immunofluorescence and enzyme immunoassay

[11] Right and left ventricular function in hospitalized children with respiratory syncytial virus infection

[12] Right and left ventricular function in hospitalized children with respiratory syncytial virus infection

[13] Analytical performances of the BD Veritor™ System for the detection of respiratory syncytial virus and influenzaviruses A and B when used at bedside in the pediatric emergency department.

[14] Development of a reverse transcription recombinase polymerase amplification assay for rapid detection of human respiratory syncytial virus.

[15] Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze

[16] Screening and pharmacodynamic evaluation of the anti-respiratory syncytial virus activity of butene lactones in vitro and in vivo.

[17] The Changes of Th17/Treg and Related Cytokines: IL-17, IL-23, IL-10, and TGF-β in Respiratory Syncytial Virus Bronchiolitis Rat Model.

[18] Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.

[19] Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series

[20] Pathogenesis of Respiratory Syncytial Virus Infection in BALB/c Mice Differs Between Intratracheal and Intranasal Inoculation.

[21] Epidemic dynamics of respiratory syncytial virus in current and future climates.

[22] Correction to: Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts (Medical Microbiology and Immunology, (2018), 207, 2, (105-115), 10.1007/s00430-017-0531-0)

[23] Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.

[24] Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort.

[25] Disease severity of respiratory syncytial virus (RSV) infection correlate to a novel set of five amino acid substitutions in the RSV attachment glycoprotein (G) in China.

[26] Multiple Respiratory Syncytial Virus Introductions Into a Neonatal Intensive Care Unit.

[27] Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment

[28] Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats

[29] Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients

[30] Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.

[31] An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection

[32] Quantitative shedding patterns of respiratory syncytial virus in infants

[33] Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.

[34] Respiratory syncytial virus infection in anti-mu-treated mice.

[35] Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

[36] Transcriptional mapping of human respiratory syncytial virus.

[37] The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species.

[38] Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

[39] Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

[40] Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

[41] RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.

[42] Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus

[43] Respiratory syncytial virus infection of human mononuclear leukocytes in vitro and in vivo

[44] Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

[45] Pathogenesis of Severe Acute Respiratory Infections in the Developing World: Respiratory Syncytial Virus and Parainfluenza Viruses

[46] Transcriptional mapping of human respiratory syncytial virus

[47] Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

[48] Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells

[49] Speculation on Pathogenesis in Death from Respiratory Syncytial Virus Infection

[50] Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1

[51] Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand

[52] Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.

[53] Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

[54] Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

[55] Activation of human eosinophils in vitro by respiratory syncytial virus

[56] Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

[57] Reinfection of mice with respiratory syncytial virus

[58] Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

[59] Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection

[60] Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial

[61] Immunity and immunopathology to respiratory syncytial virus. The mouse model

[62] Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.

[63] Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

[64] Respiratory syncytial virus. An outbreak of acute respiratory illnesses in a home for infants

[65] Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection

[66] Epidemiology of respiratory syncytial virus infection among infants and children in Chicago

[67] Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview

[68] Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein

[69] Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus

[70] Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

[71] Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

[72] Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

[73] Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections

[74] Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

[75] Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants

[76] Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

[77] Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived

[78] Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

[79] The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins

[80] Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus

[81] Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

[82] Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus

[83] Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

[84] Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

[85] Respiratory syncytial virus infection in human immunodeficiency virus-infected children

[86] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

[87] Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus

[88] EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AMONG INFANTS AND CHILDREN IN CHICAGO

[89] Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

[90] Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein.

[91] Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

[92] Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells

[93] The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species

[94] Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats

[95] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

[96] Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

[97] Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.

[98] Cytotoxic T-cell response to respiratory syncytial virus in mice.

[99] Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies

[100] Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

[101] A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection